Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
D. Viola, A. Dona, E. Caserta, E. Troadec, E. G. Gunes, F. Besi, T. McDonald, L. Ghoda, J. F. Sanchez, J. Khalife, M. Martella, C. Karanes, M. Htut, X. Wang, M. Rosenzweig, , F. Pichiorri
This study shows that daratumumab targets CD38+ NK cells to induce immune activation and anti-myeloma activity despite reducing total NK cell frequency.
bioRxiv · Nov 22, 2019Cancer Biology